Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 1319

1.

Primary Angiosarcoma of the Cervix: Case Report of a Rare Lesion.

Shah VI, Rowlands GL, Thompson IW, Sumathi VP, McCluggage WG.

Int J Gynecol Pathol. 2020 Jan;39(1):97-102. doi: 10.1097/PGP.0000000000000567.

PMID:
31815894
2.

Repeatability of Optical Coherence Tomography Angiography in Uveitic Eyes.

Caplash S, Kodati S, Cheng SK, Akanda M, Vitale S, Thompson I, Gangaputra S, Sen HN.

Transl Vis Sci Technol. 2019 Nov 15;8(6):17. doi: 10.1167/tvst.8.6.17. eCollection 2019 Nov.

3.

Everolimus Exposure as a Predictor of Toxicity in Renal Cell Cancer Patients in the Adjuvant Setting: Results of a Pharmacokinetic Analysis for SWOG S0931 (EVEREST), a Phase III Study (NCT01120249).

Synold TW, Plets M, Tangen CM, Heath EI, Palapattu GS, Mack PC, Stein MN, Meng MV, Lara P, Vogelzang NJ, Thompson IM, Ryan CW.

Kidney Cancer. 2019 Aug 7;3(2):111-118. doi: 10.3233/KCA-180049.

4.

River toxicity assessment using molecular biosensors: Heavy metal contamination in the Turag-Balu-Buriganga river systems, Dhaka, Bangladesh.

Rampley CPN, Whitehead PG, Softley L, Hossain MA, Jin L, David J, Shawal S, Das P, Thompson IP, Huang WE, Peters R, Holdship P, Hope R, Alabaster G.

Sci Total Environ. 2019 Oct 31:134760. doi: 10.1016/j.scitotenv.2019.134760. [Epub ahead of print]

PMID:
31744697
5.

Anaerobic digestion of Crassulacean Acid Metabolism plants: Exploring alternative feedstocks for semi-arid lands.

Lueangwattanapong K, Ammam F, Mason PM, Whitehead C, McQueen-Mason SJ, Gomez LD, Smith JAC, Thompson IP.

Bioresour Technol. 2019 Oct 14:122262. doi: 10.1016/j.biortech.2019.122262. [Epub ahead of print]

PMID:
31711909
6.

Independent control of the thermodynamic and kinetic properties of aptamer switches.

Wilson BD, Hariri AA, Thompson IAP, Eisenstein M, Soh HT.

Nat Commun. 2019 Nov 7;10(1):5079. doi: 10.1038/s41467-019-13137-x.

7.

CHOROIDAL LESIONS UNRESPONSIVE TO FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT IN BIRDSHOT CHORIORETINOPATHY.

Cheng SK, Thompson I, Okeagu C, Nida H.

Retin Cases Brief Rep. 2019 Oct 31. doi: 10.1097/ICB.0000000000000909. [Epub ahead of print]

PMID:
31688672
8.

African American Race is Not Associated with Risk of Reclassification during Active Surveillance: Results from the Canary Prostate Cancer Active Surveillance Study (PASS).

Schenk JM, Newcomb LF, Zheng Y, Faino AV, Zhu K, Nyame YA, Brooks JD, Carroll PR, Cooperberg MR, Dash A, Filson CP, Gleave ME, Liss M, Martin FM, Morgan TM, Nelson PS, Thompson IM, Wagner AA, Lin DW.

J Urol. 2019 Oct 25:101097JU0000000000000621. doi: 10.1097/JU.0000000000000621. [Epub ahead of print]

PMID:
31651227
9.

Variations in prostate biopsy recommendation and acceptance confound evaluation of risk factors for prostate cancer: Examining race and BMI.

Tangen CM, Schenk J, Till C, Goodman PJ, Barrington W, Lucia MS, Thompson IM.

Cancer Epidemiol. 2019 Dec;63:101619. doi: 10.1016/j.canep.2019.101619. Epub 2019 Oct 19.

PMID:
31639607
10.

5α-Reductase Inhibitor Use in Patients With Prostate Cancer.

Thompson IM Jr, Tangen CM, Kramer B.

JAMA Intern Med. 2019 Oct 1;179(10):1440. doi: 10.1001/jamainternmed.2019.3626. No abstract available.

PMID:
31589258
11.

VASOPROLIFERATIVE TUMORS IN INTERMEDIATE UVEITIS.

Pichi F, Neri P, Agarwal A, Invernizzi A, Choudhry N, Amer R, Lembo A, Nucci P, Thompson I, Sen HN, Shields CL.

Retina. 2019 Oct 1. doi: 10.1097/IAE.0000000000002656. [Epub ahead of print]

PMID:
31584561
12.

Predictors of Recurrence, and Progression-Free and Overall Survival following Open versus Robotic Radical Cystectomy: Analysis from the RAZOR Trial with a 3-Year Followup.

Venkatramani V, Reis IM, Castle EP, Gonzalgo ML, Woods ME, Svatek RS, Weizer AZ, Konety BR, Tollefson M, Krupski TL, Smith ND, Shabsigh A, Barocas DA, Quek ML, Dash A, Kibel AS, Pruthi RS, Montgomery JS, Weight CJ, Sharp DS, Chang SS, Cookson MS, Gupta GN, Gorbonos A, Uchio EM, Skinner E, Soodana-Prakash N, Becerra MF, Swain S, Kendrick K, Smith JA Jr, Thompson IM, Parekh DJ.

J Urol. 2019 Sep 24:101097JU0000000000000565. doi: 10.1097/JU.0000000000000565. [Epub ahead of print]

PMID:
31549935
13.

Systemic to Pulmonary Collaterals in Extremely Low Birth Weight Infants: Incidence, Clinical Significance, and Hemodynamic Features.

Hayek C, Cayabyab R, Thompson I, Ebrahimi M, Siassi B, Ramanathan R.

Am J Perinatol. 2019 Aug 20. doi: 10.1055/s-0039-1695012. [Epub ahead of print]

PMID:
31430815
14.

Association of dry matter intake and energy balance prepartum and postpartum with health disorders postpartum: Part I. Calving disorders and metritis.

Pérez-Báez J, Risco CA, Chebel RC, Gomes GC, Greco LF, Tao S, Thompson IM, do Amaral BC, Zenobi MG, Martinez N, Staples CR, Dahl GE, Hernández JA, Santos JEP, Galvão KN.

J Dairy Sci. 2019 Oct;102(10):9138-9150. doi: 10.3168/jds.2018-15878. Epub 2019 Jul 17.

PMID:
31326177
15.

Association of dry matter intake and energy balance prepartum and postpartum with health disorders postpartum: Part II. Ketosis and clinical mastitis.

Pérez-Báez J, Risco CA, Chebel RC, Gomes GC, Greco LF, Tao S, Thompson IM, do Amaral BC, Zenobi MG, Martinez N, Staples CR, Dahl GE, Hernández JA, Santos JEP, Galvão KN.

J Dairy Sci. 2019 Oct;102(10):9151-9164. doi: 10.3168/jds.2018-15879. Epub 2019 Jul 17.

PMID:
31326169
16.

The effectiveness of immunosuppressive cyclosporin in attenuating the progression of interstitial lung diseases.

Eapen MS, Gaikwad AV, Thompson IE, Lu W, Myers S, Sharma P, Sohal SS.

J Thorac Dis. 2019 May;11(Suppl 9):S1139-S1142. doi: 10.21037/jtd.2019.04.44. No abstract available.

17.

A genome-wide association study of prostate cancer in Latinos.

Du Z, Hopp H, Ingles SA, Huff C, Sheng X, Weaver B, Stern M, Hoffmann TJ, John EM, Van Den Eeden SK, Strom S, Leach RJ, Thompson IM Jr, Witte JS, Conti DV, Haiman CA.

Int J Cancer. 2019 Jun 21. doi: 10.1002/ijc.32525. [Epub ahead of print]

PMID:
31226226
18.

Smoking-associated AHRR demethylation in cord blood DNA: impact of CD235a+ nucleated red blood cells.

Bergens MA, Pittman GS, Thompson IJB, Campbell MR, Wang X, Hoyo C, Bell DA.

Clin Epigenetics. 2019 Jun 10;11(1):87. doi: 10.1186/s13148-019-0686-1.

19.

Copper intrauterine device placement 6-14 days after unprotected sex.

Thompson I, Sanders JN, Schwarz EB, Boraas C, Turok DK.

Contraception. 2019 Sep;100(3):219-221. doi: 10.1016/j.contraception.2019.05.015. Epub 2019 Jun 7.

PMID:
31176689
20.

Vortioxetine reverses medial prefrontal cortex-mediated cognitive deficits in male rats induced by castration as a model of androgen deprivation therapy for prostate cancer.

Sharp AM, Lertphinyowong S, Yee SS, Paredes D, Gelfond J, Johnson-Pais TL, Leach RJ, Liss M, Risinger AL, Sullivan AC, Thompson IM, Morilak DA.

Psychopharmacology (Berl). 2019 Nov;236(11):3183-3195. doi: 10.1007/s00213-019-05274-4. Epub 2019 May 28.

PMID:
31139875
21.

More on Long-Term Effects of Finasteride on Prostate Cancer Mortality. Reply.

Goodman PJ, Tangen CM, Thompson IM Jr.

N Engl J Med. 2019 May 16;380(20):e38. doi: 10.1056/NEJMc1902700. No abstract available.

PMID:
31091400
22.

Adjuvant and Salvage Radiation Therapy After Prostatectomy: ASTRO/AUA Guideline Amendment, Executive Summary 2018.

Pisansky TM, Thompson IM, Valicenti RK, D'Amico AV, Selvarajah S.

Pract Radiat Oncol. 2019 Jul - Aug;9(4):208-213. doi: 10.1016/j.prro.2019.04.008. Epub 2019 Apr 30.

PMID:
31051281
23.

Simulating morphologies of organic semiconductors by exploiting low-frequency vibrational modes.

Smith AR, Thompson IR, Walker AB.

J Chem Phys. 2019 Apr 28;150(16):164115. doi: 10.1063/1.5088895.

PMID:
31042904
24.

Adjuvant and Salvage Radiotherapy after Prostatectomy: ASTRO/AUA Guideline Amendment 2018-2019.

Pisansky TM, Thompson IM, Valicenti RK, D'Amico AV, Selvarajah S.

J Urol. 2019 Sep;202(3):533-538. doi: 10.1097/JU.0000000000000295. Epub 2019 Aug 8.

PMID:
31042111
25.

Associations between Maternal Tobacco Smoke Exposure and the Cord Blood [Formula: see text] DNA Methylome.

Howe CG, Zhou M, Wang X, Pittman GS, Thompson IJ, Campbell MR, Bastain TM, Grubbs BH, Salam MT, Hoyo C, Bell DA, Smith AD, Breton CV.

Environ Health Perspect. 2019 Apr;127(4):47009. doi: 10.1289/EHP3398.

26.

Ocular Adverse Events following Use of Immune Checkpoint Inhibitors for Metastatic Malignancies.

Noble CW, Gangaputra SS, Thompson IA, Yuan A, Apolo AB, Lee JM, Papaliodis GN, Kodati S, Bishop R, Magone MT, Sobrin L, Sen HN.

Ocul Immunol Inflamm. 2019 Apr 23:1-6. doi: 10.1080/09273948.2019.1583347. [Epub ahead of print]

PMID:
31013173
27.

A distance to the Large Magellanic Cloud that is precise to one per cent.

Pietrzyński G, Graczyk D, Gallenne A, Gieren W, Thompson IB, Pilecki B, Karczmarek P, Górski M, Suchomska K, Taormina M, Zgirski B, Wielgórski P, Kołaczkowski Z, Konorski P, Villanova S, Nardetto N, Kervella P, Bresolin F, Kudritzki RP, Storm J, Smolec R, Narloch W.

Nature. 2019 Mar;567(7747):200-203. doi: 10.1038/s41586-019-0999-4. Epub 2019 Mar 13.

PMID:
30867610
28.

LIONS: analysis suite for detecting and quantifying transposable element initiated transcription from RNA-seq.

Babaian A, Thompson IR, Lever J, Gagnier L, Karimi MM, Mager DL.

Bioinformatics. 2019 Oct 1;35(19):3839-3841. doi: 10.1093/bioinformatics/btz130.

PMID:
30793157
29.

Monitoring Cr toxicity and remediation processes - combining a whole-cell bioreporter and Cr isotope techniques.

Zhang Q, Song Y, Amor K, Huang WE, Porcelli D, Thompson I.

Water Res. 2019 Apr 15;153:295-303. doi: 10.1016/j.watres.2019.01.009. Epub 2019 Jan 21.

PMID:
30735959
30.

Long-Term Effects of Finasteride on Prostate Cancer Mortality.

Goodman PJ, Tangen CM, Darke AK, Lucia MS, Ford LG, Minasian LM, Parnes HL, LeBlanc ML, Thompson IM Jr.

N Engl J Med. 2019 Jan 24;380(4):393-394. doi: 10.1056/NEJMc1809961. No abstract available.

PMID:
30673548
31.

Performance of PCA3 and TMPRSS2:ERG urinary biomarkers in prediction of biopsy outcome in the Canary Prostate Active Surveillance Study (PASS).

Newcomb LF, Zheng Y, Faino AV, Bianchi-Frias D, Cooperberg MR, Brown MD, Brooks JD, Dash A, Fabrizio MD, Gleave ME, Liss M, Morgan TM, Thompson IM, Wagner AA, Carroll PR, Nelson PS, Lin DW.

Prostate Cancer Prostatic Dis. 2019 Sep;22(3):438-445. doi: 10.1038/s41391-018-0124-z. Epub 2019 Jan 21.

32.

Development of Aspirin-Inducible Biosensors in Escherichia coli and SimCells.

Chen JX, Steel H, Wu YH, Wang Y, Xu J, Rampley CPN, Thompson IP, Papachristodoulou A, Huang WE.

Appl Environ Microbiol. 2019 Mar 6;85(6). pii: e02959-18. doi: 10.1128/AEM.02959-18. Print 2019 Mar 15.

33.

Structural Thalamofrontal Hypoconnectivity Is Related to Oculomotor Corollary Discharge Dysfunction in Schizophrenia.

Yao B, Neggers SFW, Rolfs M, Rösler L, Thompson IA, Hopman HJ, Ghermezi L, Kahn RS, Thakkar KN.

J Neurosci. 2019 Mar 13;39(11):2102-2113. doi: 10.1523/JNEUROSCI.1473-18.2019. Epub 2019 Jan 10.

34.

Author Correction: Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci.

Schumacher FR, Olama AAA, Berndt SI, Benlloch S, Ahmed M, Saunders EJ, Dadaev T, Leongamornlert D, Anokian E, Cieza-Borrella C, Goh C, Brook MN, Sheng X, Fachal L, Dennis J, Tyrer J, Muir K, Lophatananon A, Stevens VL, Gapstur SM, Carter BD, Tangen CM, Goodman PJ, Thompson IM Jr, Batra J, Chambers S, Moya L, Clements J, Horvath L, Tilley W, Risbridger GP, Gronberg H, Aly M, Nordström T, Pharoah P, Pashayan N, Schleutker J, Tammela TLJ, Sipeky C, Auvinen A, Albanes D, Weinstein S, Wolk A, Håkansson N, West CML, Dunning AM, Burnet N, Mucci LA, Giovannucci E, Andriole GL, Cussenot O, Cancel-Tassin G, Koutros S, Beane Freeman LE, Sorensen KD, Orntoft TF, Borre M, Maehle L, Grindedal EM, Neal DE, Donovan JL, Hamdy FC, Martin RM, Travis RC, Key TJ, Hamilton RJ, Fleshner NE, Finelli A, Ingles SA, Stern MC, Rosenstein BS, Kerns SL, Ostrer H, Lu YJ, Zhang HW, Feng N, Mao X, Guo X, Wang G, Sun Z, Giles GG, Southey MC, MacInnis RJ, FitzGerald LM, Kibel AS, Drake BF, Vega A, Gómez-Caamaño A, Szulkin R, Eklund M, Kogevinas M, Llorca J, Castaño-Vinyals G, Penney KL, Stampfer M, Park JY, Sellers TA, Lin HY, Stanford JL, Cybulski C, Wokolorczyk D, Lubinski J, Ostrander EA, Geybels MS, Nordestgaard BG, Nielsen SF, Weischer M, Bisbjerg R, Røder MA, Iversen P, Brenner H, Cuk K, Holleczek B, Maier C, Luedeke M, Schnoeller T, Kim J, Logothetis CJ, John EM, Teixeira MR, Paulo P, Cardoso M, Neuhausen SL, Steele L, Ding YC, De Ruyck K, De Meerleer G, Ost P, Razack A, Lim J, Teo SH, Lin DW, Newcomb LF, Lessel D, Gamulin M, Kulis T, Kaneva R, Usmani N, Singhal S, Slavov C, Mitev V, Parliament M, Claessens F, Joniau S, Van den Broeck T, Larkin S, Townsend PA, Aukim-Hastie C, Gago-Dominguez M, Castelao JE, Martinez ME, Roobol MJ, Jenster G, van Schaik RHN, Menegaux F, Truong T, Koudou YA, Xu J, Khaw KT, Cannon-Albright L, Pandha H, Michael A, Thibodeau SN, McDonnell SK, Schaid DJ, Lindstrom S, Turman C, Ma J, Hunter DJ, Riboli E, Siddiq A, Canzian F, Kolonel LN, Le Marchand L, Hoover RN, Machiela MJ, Cui Z, Kraft P, Amos CI, Conti DV, Easton DF, Wiklund F, Chanock SJ, Henderson BE, Kote-Jarai Z, Haiman CA, Eeles RA; Profile Study; Australian Prostate Cancer BioResource (APCB); IMPACT Study; Canary PASS Investigators; Breast and Prostate Cancer Cohort Consortium (BPC3); PRACTICAL (Prostate Cancer Association Group to Investigate Cancer-Associated Alterations in the Genome) Consortium; Cancer of the Prostate in Sweden (CAPS); Prostate Cancer Genome-wide Association Study of Uncommon Susceptibility Loci (PEGASUS); Genetic Associations and Mechanisms in Oncology (GAME-ON)/Elucidating Loci Involved in Prostate Cancer Susceptibility (ELLIPSE) Consortium.

Nat Genet. 2019 Feb;51(2):363. doi: 10.1038/s41588-018-0330-6.

PMID:
30622367
35.

Using stable isotope fractionation factors to identify Cr(VI) reduction pathways: Metal-mineral-microbe interactions.

Zhang Q, Amor K, Galer SJG, Thompson I, Porcelli D.

Water Res. 2019 Mar 15;151:98-109. doi: 10.1016/j.watres.2018.11.088. Epub 2018 Dec 19.

PMID:
30594094
36.

Overall Survival of Black and White Men With Metastatic Castration-Resistant Prostate Cancer Treated With Docetaxel.

Halabi S, Dutta S, Tangen CM, Rosenthal M, Petrylak DP, Thompson IM Jr, Chi KN, Araujo JC, Logothetis C, Quinn DI, Fizazi K, Morris MJ, Eisenberger MA, George DJ, De Bono JS, Higano CS, Tannock IF, Small EJ, Kelly WK.

J Clin Oncol. 2019 Feb 10;37(5):403-410. doi: 10.1200/JCO.18.01279. Epub 2018 Dec 21.

37.

Case-only Methods Identified Genetic Loci Predicting a Subgroup of Men with Reduced Risk of High-grade Prostate Cancer by Finasteride.

Dai JY, LeBlanc M, Goodman PJ, Lucia MS, Thompson IM, Tangen CM.

Cancer Prev Res (Phila). 2019 Feb;12(2):113-120. doi: 10.1158/1940-6207.CAPR-18-0284. Epub 2018 Dec 11.

PMID:
30538099
38.

Primary Angiosarcoma of the Cervix: Case Report of a Rare Lesion.

Shah VI, Rowlands GL, Thompson IW, Sumathi VP, McCluggage WG.

Int J Gynecol Pathol. 2018 Dec 3. doi: 10.1097/PGP.0000000000000567. [Epub ahead of print]

PMID:
30516618
39.

Optical coherence tomography angiography characteristics in diabetic patients without clinical diabetic retinopathy.

Thompson IA, Durrani AK, Patel S.

Eye (Lond). 2019 Apr;33(4):648-652. doi: 10.1038/s41433-018-0286-x. Epub 2018 Dec 3.

PMID:
30510234
40.

Heparin-binding epidermal growth factor (HB-EGF) drives EMT in patients with COPD: implications for disease pathogenesis and novel therapies.

Eapen MS, Sharma P, Thompson IE, Lu W, Myers S, Hansbro PM, Sohal SS.

Lab Invest. 2019 Feb;99(2):150-157. doi: 10.1038/s41374-018-0146-0. Epub 2018 Nov 19. Review.

PMID:
30451982
41.

Higher baseline dietary fat and fatty acid intake is associated with increased risk of incident prostate cancer in the SABOR study.

Liss MA, Al-Bayati O, Gelfond J, Goros M, Ullevig S, DiGiovanni J, Hamilton-Reeves J, O'Keefe D, Bacich D, Weaver B, Leach R, Thompson IM.

Prostate Cancer Prostatic Dis. 2019 May;22(2):244-251. doi: 10.1038/s41391-018-0105-2. Epub 2018 Nov 1.

PMID:
30385837
42.

Parallel (Randomized) Phase II Evaluation of Tivantinib (ARQ197) and Tivantinib in Combination with Erlotinib in Papillary Renal Cell Carcinoma: SWOG S1107.

Twardowski PW, Tangen CM, Wu X, Plets MR, Plimack ER, Agarwal N, Vogelzang NJ, Wang J, Tao S, Thompson IM, Lara P.

Kidney Cancer. 2017 Nov 27;1(2):123-132. doi: 10.3233/KCA-170018.

43.

The effect of 3-month finasteride challenge on biomarkers for predicting cancer outcome on biopsy: Results of a randomized trial.

Hernandez J, Gelfond J, Goros M, Liss MA, Liang Y, Ankerst D, Thompson IM Jr, Leach RJ.

PLoS One. 2018 Oct 9;13(10):e0204823. doi: 10.1371/journal.pone.0204823. eCollection 2018.

44.

Role of Genetic Susceptibility in the Development of Bronchopulmonary Dysplasia.

Parad RB, Winston AB, Kalish LA, Gupta M, Thompson I, Sheldon Y, Morey J, Van Marter LJ.

J Pediatr. 2018 Dec;203:234-241.e2. doi: 10.1016/j.jpeds.2018.07.099. Epub 2018 Oct 1.

PMID:
30287068
45.

A Prospective Adaptive Utility Trial to Validate Performance of a Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer in Patients with Prostate-specific Antigen 2-10ng/ml at Initial Biopsy.

McKiernan J, Donovan MJ, Margolis E, Partin A, Carter B, Brown G, Torkler P, Noerholm M, Skog J, Shore N, Andriole G, Thompson I, Carroll P.

Eur Urol. 2018 Dec;74(6):731-738. doi: 10.1016/j.eururo.2018.08.019. Epub 2018 Sep 17.

46.

FIVE-YEAR FUNCTIONAL OUTCOMES AFTER EPIRETINAL MEMBRANE SURGERY: A Prospective, Controlled Study.

Jonna G, Thompson IA, Mendel TA, Kim SJ.

Retina. 2019 Dec;39(12):2326-2331. doi: 10.1097/IAE.0000000000002323.

PMID:
30234853
47.

Experimental Evidence of a Variant Neutron Spectrum from the T(t,2n)α Reaction at Center-of-Mass Energies in the Range of 16-50 keV.

Gatu Johnson M, Forrest CJ, Sayre DB, Bacher A, Bourgade JL, Brune CR, Caggiano JA, Casey DT, Frenje JA, Glebov VY, Hale GM, Hatarik R, Herrmann HW, Janezic R, Kim YH, Knauer JP, Landoas O, McNabb DP, Paris MW, Petrasso RD, Pino JE, Quaglioni S, Rosse B, Sanchez J, Sangster TC, Sio H, Shmayda W, Stoeckl C, Thompson I, Zylstra AB.

Phys Rev Lett. 2018 Jul 27;121(4):042501. doi: 10.1103/PhysRevLett.121.042501.

PMID:
30095940
48.

Low Free Testosterone and Prostate Cancer Risk: A Collaborative Analysis of 20 Prospective Studies.

Watts EL, Appleby PN, Perez-Cornago A, Bueno-de-Mesquita HB, Chan JM, Chen C, Cohn BA, Cook MB, Flicker L, Freedman ND, Giles GG, Giovannucci E, Gislefoss RE, Hankey GJ, Kaaks R, Knekt P, Kolonel LN, Kubo T, Le Marchand L, Luben RN, Luostarinen T, Männistö S, Metter EJ, Mikami K, Milne RL, Ozasa K, Platz EA, Quirós JR, Rissanen H, Sawada N, Stampfer M, Stanczyk FZ, Stattin P, Tamakoshi A, Tangen CM, Thompson IM, Tsilidis KK, Tsugane S, Ursin G, Vatten L, Weiss NS, Yeap BB, Allen NE, Key TJ, Travis RC.

Eur Urol. 2018 Nov;74(5):585-594. doi: 10.1016/j.eururo.2018.07.024. Epub 2018 Aug 1.

49.

mTOR inhibitors for treatment of low-risk prostate cancer.

Liss MA, Rickborn L, DiGiovanni J, Bacich D, DeGraffenried LA, Parihar M, Thompson IM, Sharp ZD.

Med Hypotheses. 2018 Aug;117:63-68. doi: 10.1016/j.mehy.2018.06.004. Epub 2018 Jun 5.

50.

Continued 5α-Reductase Inhibitor Use after Prostate Cancer Diagnosis and the Risk of Reclassification and Adverse Pathological Outcomes in the PASS.

Kearns JT, Faino AV, Schenk JM, Newcomb LF, Brooks JD, Carroll PR, Dash A, Ellis WJ, Fabrizio M, Gleave ME, Morgan TM, Nelson PS, Thompson IM, Wagner A, Zheng Y, Lin DW.

J Urol. 2019 Jan;201(1):106-111. doi: 10.1016/j.juro.2018.07.065.

PMID:
30076904

Supplemental Content

Loading ...
Support Center